Kestra Medical Technologies (NASDAQ:KMTS) Announces Quarterly Earnings Results

Key Points

• Kestra Medical Technologies reported a quarterly EPS of ($0.46), exceeding analysts' expectations of ($0.66) by $0.20.
• The company's stock price increased by 1.2% to $18.40, with a significant trading volume of 458,173 shares.
• Wells Fargo lowered its price target for Kestra Medical Technologies from $28.00 to $27.00, while the stock maintains a consensus rating of "Moderate Buy".

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.20, Zacks reports. Kestra Medical Technologies updated its FY 2026 guidance to EPS.

Kestra Medical Technologies Trading Up 1.2%

KMTS traded up $0.21 during trading on Thursday, reaching $18.40. The company had a trading volume of 458,173 shares, compared to its average volume of 272,327. The company has a 50-day moving average of $16.28. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.20. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $26.15.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KMTS. Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 10.8% during the 2nd quarter. Alliancebernstein L.P. now owns 1,312,085 shares of the company's stock worth $21,754,000 after purchasing an additional 128,312 shares in the last quarter. Armistice Capital LLC raised its stake in shares of Kestra Medical Technologies by 82.7% during the 2nd quarter. Armistice Capital LLC now owns 22,834 shares of the company's stock worth $379,000 after purchasing an additional 10,334 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Kestra Medical Technologies by 46.8% during the second quarter. The Manufacturers Life Insurance Company now owns 42,653 shares of the company's stock valued at $707,000 after acquiring an additional 13,599 shares in the last quarter. Sei Investments Co. acquired a new position in shares of Kestra Medical Technologies during the 2nd quarter worth $513,000. Finally, Walleye Capital LLC bought a new position in shares of Kestra Medical Technologies during the 2nd quarter valued at $166,000.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company decreased their price target on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of "Moderate Buy" and a consensus price target of $27.33.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.